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Abstract
Every year, ovarian cancer kills approximately 14,000 women in the United States and more than 140,000 women
worldwide. Most of these deaths are caused by tumors of the serous histological type, which is rarely diagnosed before it
has disseminated. By deep paired-end sequencing of mRNA from serous ovarian cancers, followed by deep sequencing of
the corresponding genomic region, we identified a recurrent fusion transcript. The fusion transcript joins the 59 exons of
ESRRA, encoding a ligand-independent member of the nuclear-hormone receptor superfamily, to the 39 exons of C11orf20,
a conserved but uncharacterized gene located immediately upstream of ESRRA in the reference genome. To estimate the
prevalence of the fusion, we tested 67 cases of serous ovarian cancer by RT-PCR and sequencing and confirmed its presence
in 10 of these. Targeted resequencing of the corresponding genomic region from two fusion-positive tumor samples
identified a nearly clonal chromosomal rearrangement positioning ESRRA upstream of C11orf20 in one tumor, and evidence
of local copy number variation in the ESRRA locus in the second tumor. We hypothesize that the recurrent novel fusion
transcript may play a role in pathogenesis of a substantial fraction of serous ovarian cancers and could provide a molecular
marker for detection of the cancer. Gene fusions involving adjacent or nearby genes can readily escape detection but may
play important roles in the development and progression of cancer.
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Introduction
Ovarian cancer is estimated to kill more than 140,000 women
every year [1]. Like most cancers, ovarian cancer has a dismal
prognosis once the disease has spread beyond the site of origin [2].
The histological subtypes of ovarian cancer differ substantially in
their molecular features and natural history and can be considered
distinct diseases. Ovarian carcinomas of the serous histological type
are responsible for the majority of deaths from ovarian cancer; they
typically progress to an advanced stage while the tumor is still much
too small to be detected by any presently available screening
method [3]. Discovery of truly tumor-specific molecular markers
may be essential for effective early detection of these tumors.
Recurrent gene fusions are among the most tumor-specific
molecular markers known. Investigations of oncogenic gene
fusions, including BCR-ABL in chronic myelogenous leukemia,
have provided critical insights into pathogenesis and led to
important therapeutic advances [4].
With a few notable exceptions, however, recurrent gene fusions
have rarely been identified in commonly occurring carcinomas,
which often have multiple, complex chromosomal rearrangements
that are difficult to analyze by traditional cytogenetic approaches.
A recurrent gene fusion, TMPRSS2-ERG, with an estimated
prevalence of ,50% in prostate cancer was discovered by a
targeted search for cancer-associated genes with anomalous
expression patterns, in a large database of DNA microarray data
[5]. An ex vivo functional screen of cDNA from a non-small cell
lung carcinoma (NSCLC) led to identification of EML4-ALK as a
recurrent gene fusion in ,5% of NSCLCs [6,7].
Ultra High Throughput Sequencing (UHTS) is a powerful
method for discovery of novel RNA sequences, including cancer-
specific gene fusions. Tumor-specific genomic rearrangements and
fusion transcripts have been discovered in individual tumors by
UHTS (see for example [8–10]), including in high-grade serous
ovarian cancer [11], but none of those reported to date have been
recurrent. For example, a UHTS survey of genomic aberrations in
24 breast cancers found more than 2,000 rearrangements; 29 of
these were predicted to generate in-frame gene fusions, but none
occurred in more than one individual [12]. Similarly, a UHTS
analysis of RNA from 10 melanomas identified 11 gene fusions,
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additional cases [10].
We combined deep, paired-end sequencing of tumor RNA with
a statistical bioinformatic approach to search for gene fusions in a
pool of mRNA isolated from 12 primary serous ovarian cancers.
Our analysis identified a novel recurrent gene fusion, ESRRA-
C11orf20, resulting from a chromosomal rearrangement. The
methods we used have important differences from previous
algorithms for identifying gene fusions and novel splice variants
[8–10], mainly in the use of statistical models for fusion discovery,
and may be useful for discovering gene fusions in other cancers.
(Note: since the algorithm used to identify the ESRRA-C11orf20
fusion was built, other algorithms for detecting fusions with RNA-
Seq have been published [11,13] with methods related to but
algorithmically distinct from ours.)
Results
UHTS Analysis of RNA from Serous Ovarian Cancer
Identifies a Candidate Gene Fusion
To search for recurrent or highly expressed fusion transcripts,
we first prepared a cDNA library with an average insert size of
350 bp from a pool of 12 late-stage serous ovarian tumors. Using
Illumina GA II instruments, we determined 30 million pairs of 76-
nucleotide sequences and 80 million pairs of 38-nucleotide
sequences from the ends of these cDNA segments, a total of 111
million purity filtered (PF) reads.
Our RNA sequence analysis pipeline is diagrammed in Figure
S1. We began by identifying paired reads that mapped uniquely to
any two distinct genes (call them genes A and B). However, most
such paired reads are spurious, due to artifactual ligation during
library preparation, sequencing errors, or paralogous sequences.
We constructed a database of the sequences predicted for every
possible exon-exon junction that might result from a fusion
between such pairs of genes A and B in the RefSeq database. We
then searched our sequence data for individual reads that failed to
align to the RefSeq transcript database, but did align uniquely to a
sequence in our database of hypothetical gene fusion exon-exon
junctions (‘‘junction reads’’). To be considered further, we also
required that any such sequence have at least 10 bp aligning to
each side of the hypothetical junction and that its cognate paired-
end read align to one of the corresponding fusion partners in an
orientation consistent with the predicted A-B fusion (diagrammed
in Figure S2). Rather than introduce more stringent filters to
exclude potential artifacts, at the expense of discarding potentially
important results, we used statistical models to estimate the
distribution of falsely identified fusions and assess a false discovery
rate (see Text S1).
A transcript composed of exons from the ESRRA and C11orf20
genes was one of two putative fusion transcripts supported by more
than three junction reads. (The other appeared to be a read-
through transcript and has subsequently been annotated as RefSeq
gene LOC100630923. The full list of candidates is given in Table
S2.) Two distinct splice variants of a hypothetical fusion between
ESRRA and C11orf20, joining exon 2 of ESRRA to either exon 3
or exon 4 of C11orf20 (E2-C3 and E2-C4, Figure 1B), were
represented, E2-C3 with a low estimated false-discovery rate. We
confirmed both of these predicted fusion transcripts by using RT-
PCR to amplify the diagnostic exon junction sequences from pool
RNA, followed by Sanger sequencing (Figure S3).
ESRRA (Estrogen Receptor Related Alpha, also known as
ERR1) encodes a well-studied orphan nuclear receptor related to
the estrogen receptor, and implicated in regulation of energy
metabolism and thermogenesis, its expression level has been
positively correlated with breast cancer progression and angio-
genesis ([14–18]; review in [19]). In ovarian cancer, ESRRA
expression has also been associated with decreased survival [20],
and kaempferol, which inhibits angiogenesis by ovarian cancer cell
lines, acts at least partially by decreasing ESRRA expression [21].
Very recently, the ESRRA locus has been implicated in increased
risk of ovarian cancer [22]. By contrast, C11orf20 is a mostly
uncharacterized gene, though conserved in the mammalian
lineage.
Using single read count data [23], we estimated the expression
level of ESRRA to be roughly 2500
th in abundance in our serous
ovarian cancer pool, similar to the abundance, for example, of
ESR1 (ranked ,2700
th) and TP53 (ranked ,1700
th). Based on a
statistical model for mRNA isoforms in paired-end data [24], we
estimated the relative abundance of the canonical ESRRA
mRNA, the fusion transcript E2-C3, the fusion transcript E2-
C4, and the canonical C11orf20 mRNA as 40:10:1:0, respectively.
The abundance of the fusion transcripts thus appeared to be
comparable to or greater than that of the ESRRA transcript itself,
in one or more tumors harboring the fusion. We found no
evidence for expression of either the reciprocal fusion product or
the predicted full-length C11orf20 transcript.
Recurrence and Alternatively Spliced Variants of ESRRA-
C11orf20
We evaluated the prevalence of the ESRRA-C11orf20 fusion in
a set of 68 patients with serous ovarian cancer, by RT-PCR
followed by Sanger sequencing. Nine of the 42 cases screened at
the FHCRC and 1 of the 25 cases screened at the BCCA were
fusion-positive (exemplary positive RT-PCRs in Figure 1C). This
gives an estimated prevalence of ESRRA-C11orf20 fusion
transcripts in serous ovarian cancer as 10 in 67, or 15% (exact
binomial 95% confidence interval: 7% to 26%). It should be noted
that, in order for a patient sample to be called fusion-positive, we
required that the majority of technical PCR replicates be positive;
some cases showed fusion products but less reproducibly and so
our counts may be subject to false negatives; thus this prevalence
may be an under-estimate.
Author Summary
Serous ovarian cancer, the most common form of ovarian
cancer, is especially lethal because it is usually only
detected at a late stage in its progression, after the cancer
has spread to other tissues. We searched for molecular
markers of this cancer that might provide a better way to
detect tumors at a curable stage and that might provide
targets for new treatments. Chromosomal rearrangements
that fuse two genes to produce a recombinant gene that
enhances growth or spread of the cancer are particularly
specific biomarkers and have been found in many cancers.
By ‘‘deep’’ sequencing of the RNA molecules that carry
genetic information in serous ovarian cancers, we discov-
ered a rearrangement that fuses the same two neighbor-
ing genes in at least 15% of these tumors. The two fused
genes are ESRRA, which encodes a key regulator of gene
expression, and an essentially uncharacterized gene,
C11orf20, that is normally adjacent to the ESRRA gene.
Chromosomal rearrangements that recombine parts of
two nearby genes or even parts of a single gene may be a
common, important feature of the cancer genome that
eludes detection by most approaches to characterizing
cancer genomes.
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ESRRA-C11orf20 fusion isoforms previously observed in our
tumor pool (E2-C3, E2-C4). One patient expressed exclusively a
third isoform (E2-C5) in which ESRRA exon 2 was spliced to exon
5 of C11orf20 (Patient 3, Figure 1C).
The ESRRA protein consists of an N-terminal regulatory
domain (NTD), a DNA binding domain (DBD) comprising two
zinc-fingers, and a putative ligand-binding domain (LBD) [19].
The fusion transcripts all encode the NTD and the first zinc-finger
of the DBD, but lack both the second zinc-finger and the LBD.
Two of the three fusion transcripts preserve reading frame across
the junction (E2-C3 and E2-C5); both share sequences encoding
the 35 C-terminal amino acids of the predicted C11orf20 protein,
including a basic potential nuclear-localization signal (Figure 1D).
The E2-C4 junction introduces a frameshift, resulting in a
nonsense codon shortly after the junction (Figure 1B). All fusion-
positive tumors we have identified expressed at least one of the in-
frame isoforms.
Genomic Rearrangement in the C11orf20-ESRRA Locus
In principle, the ESRRA-C11orf20 fusion transcripts could
have resulted from: (1) an acquired or germline rearrangement of
the C11orf20-ESRRA region of Chromosome 11 deviating from
that in reported human reference genomes or reported variants (to
our knowledge, no germline structural variant rearranging
ESRRA and C11orf20’s relative positions has been reported,
including in the 1000 genomes project.), or (2) trans-splicing of
ESRRA and C11orf20 transcripts from an unrearranged locus. To
discriminate these possibilities, we used a hybridization-selection
and UHTS strategy to deeply sequence the C11orf20-ESRRA
genomic region in two tumors that were positive for the fusion
transcripts E2-C3 and E2-C4. A matched normal PBMC sample
chromosome 11q13.1
C11orf20 ESRRA
1 2 3 4 5 6 7 2 3 4 5 1
E2-C3 in-frame fusion 34 5 1 2
E2-C4 frameshift 4 5 1 2
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Figure 1. Fusion transcripts identified in serous ovarian cancers. (A) C11orf20 is an ORF transcribed from a region whose 59 end is less than
1 kb upstream of ESRRA’s transcriptional start in the wild-type genomic organization of 11q13.1. (B) Three isoforms of a fusion transcript, ESRRA-
C11orf20, inconsistent with a wild-type genomic organization and canonical transcription have been detected by our sequence analysis of RNA from
serous ovarian cancer cases. Each fusion isoform joins ESRRA exon 2 to a distinct exon of C11orf20. E2-C3 and E2-C5 are in frame events; E2-C4 is out
of frame and has been detected in combination with E2-C3. (C) Representative RT-PCR reactions demonstrating the presence of the fusion in 5
individual cases. Patient 1–4 were from FHCRC and Patient 5 was from BCCA. Fusions were confirmed by Sanger sequencing; the specific fusion
variants seen are detailed in Table S1. (D) All fusions are predicted to contain the N-terminal 108 amino acids of ESRRA, including the DNA-binding
zinc finger and P-Box, and conserved phosphorylation and sumoylation sites (Ser 19, Lys 14, respectively); in-frame fusions all contain the C-terminal
portion of C11orf20 with a basic putative nuclear-localization signal.
doi:10.1371/journal.pbio.1001156.g001
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presented here used original genomic DNA for library generation;
initial attempts using phi29-amplified DNA gave apparently
unreliable results.
Paired-end sequencing libraries were prepared from the three
samples (a tumor/normal matched pair and one tumor lacking a
matched normal). A 166 kb bacterial artificial chromosome (BAC)
was used to enrich for reads in the ESRRA locus. The resulting
enriched libraries were each sequenced in one lane of an Illumina
GA IIx flowcell at an average sequencing depth of 8 million
mapped 80 bp PE reads. The sequenced libraries all showed
significant inhomogeneity in sequencing depth across the targeted
interval (see Text S1); however, the inhomogeneous coverage was
consistent between samples, allowing us to model copy number
variation in the sequenced tumors by comparison to the normal
PBMC sample.
Our genomic analysis strategy is summarized as follows and
detailed in Text S1. Paired ends uniquely mapping to a 20 kb
radius of ESRRA, whose joint chromosomal coordinates and
orientations inconsistent with the reference genome were flagged.
In Tumor 1, a statistically significant ‘‘pile’’ of PE reads predicted
that ESRRA intron 2 had been rearranged upstream of C11orf20
exon 3. This hypothesis was tested using PCR to amplify the
predicted rearrangement (PCR1, Figure 2A) and a computational
method described below, both of which confirmed the expected
breakpoint (sequence in Text S1).
Because the breakpoint in Tumor 1 is flanked by a SINE repeat
both upstream in ESRRA and downstream in C11orf20, we
performed additional PCRs using primers external to those in the
first PCR, in parallel, on Tumor 1 DNA and negative control
normal DNA, to rule out an in vitro PCR artifact. Each of these
(PCR2, PCR3) produced a tumor-specific band of expected size,
and the sequenced products showed the identical breakpoint.
In parallel with PCR confirmation, an unbiased computational
approach using the de novo assembly program Velvet [25,26] was
used as a discovery tool (‘‘orphan-end assembly’’). Briefly, for each
200 bp window in the reference genome, all PE reads where one
side aligned the reference in this window and the other side failed
an alignment to the reference were flagged. The reads failing
alignment were assembled using Velvet, and screened to
determine if they supported a rearrangement placing ESRRA
upstream of C11orf20. The breakpoint sequence discovered with
PCR was also found using this computational method, and no
other breakpoint providing a parsimonious explanation for an
ESRRA-C11orf20 fusion was discovered in Tumor 1 or the other
tumor (see Text S1). Furthermore, while Illumina library reads
from Tumor 1 tiled the breakpoint, no Illumina sequence reads
from any other library aligned to it.
Finally, copy number analysis of Tumor 1 (Figure 2B) shows a
relative copy number increase precisely in the region between the
reference coordinates defining the breakpoint (and nowhere else in
the targeted region, analysis not shown). The simplest model to
account for the junctional sequence and copy number data for
Tumor 1 is that a tandem duplication of an interval between
C11orf20 and ESRRA is present in one of two diploid copies of
chromosome 1, as depicted in Figure 2A. Thus, sequence analysis
provides strong evidence that the ESRRA-C11orf20 fusions in
Tumor 1 are transcriptional products of a genomic rearrangement
that positions ESRRA upstream of C11orf20 (rather than trans-
splicing).
Tumor 2 shows significant copy number variation in the
C11orf20 and ESRRA locus (Figure 2B), as well as a large degree
of copy number variation throughout the region enriched by the
BAC (analysis not shown). Although this is evidence for a genomic
rearrangement in Tumor 2 in the critical region, we have not been
able to pinpoint a breakpoint sequence with UHTS analysis for
anomalously mapping read-pairs and orphan-end assembly, nor
by long-range genomic PCR. Several types of rearrangements
might not be detected by our short-read detection approach: for
example, a complex rearrangement including ectopic sequence
that does not hybridize to the BAC or a rearrangement within a
region of ESRRA and C11orf20 that cannot be uniquely assigned
to either gene. A substantial fraction of this region falls in a ‘‘blind
spot’’ of this method: 10% of 80-mers in ESRRA (1,008 of 10,078)
and 7% in C11orf20 (378 of 4,962) have more than 10 matches to
the human genome (hg19 build).
Discussion
We used UHTS analysis of RNA from a pool of tumor samples
in a deliberate search for a recurrent gene fusion in serous ovarian
cancer, a deadly cancer for which there is currently no early-
detection screen and in which no recurrent gene fusions had been
identified. Systematic analysis of the sequence data revealed novel
fusion transcripts combining 59 exons from ESRRA, a gene
encoding a transcription factor of the nuclear hormone receptor
family, and 39 exons from C11orf20, an uncharacterized but
phylogenetically conserved gene immediately upstream of ESRRA
on Chromosome 11. In an RT-PCR/Sanger sequencing survey of
serous ovarian cancers at two different institutions, we confirmed
ESRRA-C11orf20 fusion transcripts in 10 of the 67 tumors, or
15% (95% confidence interval: 7% to 26%), suggesting that this
fusion is present in a significant fraction of serous ovarian cancers.
To test the hypothesis that the ESRRA-C11orf20 fusion was the
result of a genomic rearrangement, we combined hybridization
selection of the C11orf20-ESRRA genomic region of Chromo-
some 11 with UHTS to analyze the structure of this interval in two
tumors. The results provide strong evidence that a fusion
transcript arose from a genomic rearrangement of the C11orf20-
ESRRA region of Chromosome 11 in one tumor and copy-
number variation evidence of rearrangement in the second tumor.
The ESSRA-C11orf20 fusion is, to our knowledge, the first
recurrent gene fusion to be identified in serous ovarian cancer.
This fusion gene and its components are now high-priority targets
for further investigation of their potential roles in pathogenesis and
as potential diagnostic or therapeutic targets. Our findings cast a
spotlight on ESRRA as a candidate oncogene in serous ovarian
cancer. ESRRA has been most studied in the context of breast
cancer: it is a negative prognostic marker in ER(–) tumors [14,15],
and it induces VEGF mRNA expression and contributes to the
malignant phenotype of a breast cancer cell line [16,17]. It has
been less studied in ovarian cancer, but has recently been
associated with increased risk of ovarian cancer [22] and
decreased patient survival [20].
Two of the three fusion isoforms we observed, E2-C3 and E2-
C5, are in-frame and predicted to encode fusion proteins that
contain the N-terminal portion of the ESRRA protein and the C-
terminal portion of the predicted C11orf20 protein. Although one
of the two zinc-finger domains and the putative ligand-binding
domain of ESRRA are absent from the predicted fusion protein,
important functional features of ESRRA are retained, including
the first zinc-finger domain, critical for the DNA sequence
specificity of ESRRA, as well as a phosphorylation site (Ser 19)
and a phosphorylation-dependent sumoylation site (Lys 14) that
have been shown to regulate transcriptional activation by ESRRA
[19]. C11orf20 is a largely uncharacterized gene, with expression
reportedly restricted to testis in mouse (RIKEN cDNA
1700019N12; [27]) and human (http://biogps.gnf.org). The
A Recurrent Gene Fusion in Ovarian Cancer
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but uncharacterized; it lacks any known functional domains and
has no apparent homology to any protein of known function.
Although any functional role for the ESSRA-C11orf20 fusion
remains to be established, fusions to other nuclear hormone
receptor transcription factors have been found in other cancers,
including PAX8–PPARG in follicular thyroid tumors [28],
EWSR1-NR4A3 in extraskeletal myxoid chondrosarcomas [29],
and PML-RARA in acute promyelocytic leukemia [30]. In those
fusions the nuclear receptor portion comprises the C-terminal
component of the fusion protein and contains the entire DNA-
binding and ligand-binding domains, whereas in the fusions
reported here, the ESRRA component is N-terminal and contains
only the first half of the DNA-binding domain (P-box zinc finger).
Single zinc fingers, however, can mediate DNA-binding, for
example in GATA-1 and SUPERMAN; in these known examples,
Figure 2. Genomic rearrangements in patient samples. Data for genomic structures of tumors analyzed with respect to the reference human
genome, build hg19. C11orf20 and ESRRA regions are color-coded and exons numbered. KCNK4 is the gene immediately upstream of C11orf20 and
PRDX5 is the gene immediately downstream of ESRRA. (A) Model for Tumor 1 DNA rearrangement. Brackets indicate a genomic interval (coordinates
ch11:64,070,517-64,079,032) from upstream of C11orf20 exon 3 to downstream of ESRRA exon 2, tandemly duplicated in the tumor (model shown
above the reference). The transcripts (E2-C3 and E2-C4) expressed by the tumor are pictured above the rearrangement model, as are the extents of
three PCR products spanning the breakpoint (PCR1, PCR2, PCR3). (B) Copy number plots for two tumors. The point estimate for copy number (as a
dot) and 95% confidence interval (as error bars) are shown for each sequence interval (bin) with reliable counts. These were computed by grouping
single aligned reads into 100 bp bins after removing potential PCR duplicates and comparing to the corresponding bin from the normal PBMC
sample. For Tumor 1, copy number estimate interior to breakpoints is approximately 1.56the copy number exterior to breakpoints, consistent with
the model in (A), where one of two diploid chromosomes has a tandem duplication. For Tumor 2, inspection of the 95% error bars indicates that
Tumor 2 exhibits statistically significant copy number variation within ESRRA intron 2, as well as at additional points.
doi:10.1371/journal.pbio.1001156.g002
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noteworthy that the in-frame fusions we identified join the
ESRRA P-box zing finger to a basic sequence in the C11orf20
C-terminus (Figure 1).
We have presented evidence that a tumor-specific ESRRA-
C11orf20 fusion transcript is present in a substantial fraction of
serous ovarian cancers and that in one of two profiled tumors,
Tumor 1, a genomic rearrangement that can account for the
fusion transcript is present in a majority of tumor cells. Copy
number variation at the ESRRA locus also suggests a structural
rearrangement in Tumor 2. Although it remains possible that the
ESRRA-C11orf20 fusion is an incidental consequence of another,
functionally important, genetic event or that it is merely a
‘‘passenger,’’ the apparent frequency with which this rearrange-
ment occurs in serous ovarian cancer and the lack of evidence that
it accompanies large-scale structural variation (such as gene
amplification) are more suggestive of a direct role.
Several characteristics of the ESRRA-C11orf20 rearrangement
reinforce themes emerging from high-resolution studies of both
normal human genetic variation [33,34] and cancer-specific
genomic alterations. Indeed, although none were found to be
recurrent, 4 of the 11 gene fusions identified in a previous UHTS
survey of RNA from a series of melanomas were strikingly similar
to the ESRRA-C11orf20 fusion; adjacent genes in the same
transcriptional orientation were rearranged to yield a fusion
transcript in which the order of the two participating genes was
reversed [10]. In a second study, using UHTS to profile genomic
rearrangements in 24 breast cancers, the overwhelming majority
of rearrangements identified were intrachromosomal; more than
90% of these involved breakpoints separated by 2 Mb or less [12].
These rearrangements, like the ESRRA-C11orf20 rearrangement
described here, are consistent with a model in which double-strand
breaks are preferentially repaired by joining sequences in physical
proximity [35–37]. Most such fine-scale genomic rearrangements,
including the ESRRA-C11orf20 rearrangement, cannot be
detected by traditional cytogenetic methods, nor, unless they lead
to extensive copy-number alterations, by array CGH. ‘‘Exome
sequencing’’ will generally fail to detect any chromosomal
rearrangement, except for the rare cases in which a breakpoint
falls within an exon. A very recent large integrated genomics
survey indeed found that high-grade serous ovarian carcinoma is
characterized by a higher degree of somatic copy-number
alterations and lower degree of somatic point mutations than the
previously surveyed cancer glioblastoma [38]; however, the
methods employed were unlikely to (and did not) identify the
rearrangement presented here. We were able to detect the
ESRRA-C11orf20 fusion, based on UHTS analysis of either
RNA or genomic DNA, only by conducting a deliberate focused
search for evidence of structural rearrangements. We suggest that
chromosomal rearrangements involving nearby or adjacent genes
may comprise a substantial fraction of oncogenic mutations that
have heretofore escaped detection.
Materials and Methods
Specimen Collection
Ovarian cancer samples and matched controls were collected
following procedures approved by the IRB at each institution:
from the Pacific Ovarian Cancer Research Consortium (POCRC)
and Fred Hutchinson Cancer Research Center (FHCRC), and
from the British Columbia Cancer Agency (BCCA) Tumour
Tissue Repository, Victoria, BC, a member of the Canadian
Tumour Repository Network. Samples were (1) collected at initial
debulking surgery using standardized protocols and (2) reviewed
by a gynecological research pathologist to confirm the histological
characteristics of the tissue; all tumor samples used in this article
contained at least 70% malignant epithelium. Clinical data for
RT-PCR screened samples are shown in Table S1.
RNA-SEQ Library Preparation
RNA was pooled from 12 high grade serous stage III/IV
carcinoma of the ovary samples together with doping control RNA
(see Text S1). 10 micrograms total RNA was diluted with water to
50 microliters, heated to 70 uC for 5 min, and purified with
DYNAL DynaBeads Oligo (dT)25 (Invitrogen, Carlsbad, CA,
USA) per manufacturer protocol. RNA was fragmented to an
average size of 350 bp by alkaline hydrolysis: RNA was added to
preheated fragmentation buffer (50 mM sodium carbonate/
bicarbonate, 1 mM EDTA, pH 9.2) and incubated at 95 uC for
6 min, then neutralized with 1/10 volume of 3 M sodium acetate
pH 5.2, and precipitated with 3 volumes ice-cold EtOH. The
pellet was washed with 75% EtOH, dried, and resuspended in
water.
First and second strand cDNA synthesis, end repair, 39-dA tail
addition, and paired-end adaptor ligation were performed using
standard protocols and reagents from the PAIRED-END Sample
Prep Kit (part # 1001809, Illumina, San Diego, CA, USA). cDNA
products were resolved by electrophoresis in 2% low-melting
agarose gels, one sample per gel. The gels were stained with SYBR
Gold (Invitrogen) and visualized on a blue light table (Dark
Reader, Clare Chemical Research, Dolores, CO). The desired
band was excised with sterile scalpels and purified with a
QIAquick Gel Extraction kit with the modifications described in
[39] to minimize GC-bias. Each sample was amplified with
Phusion DNA Polymerase and Illumina primers PE 1.0 and PE
2.0 for 15 cycles, then purified with a QIAquick PCR purification
kit per Illumina library preparation protocol.
The concentration of each sample was determined using an
Agilent Bioanalyzer. Samples were then diluted to a concentration
of 10 pM as specified by Illumina protocols. The sample derived
from pooled tumor RNA was subjected to 76-base, paired-end
sequencing in two lanes of an Illumina Genome Analyzer II and,
in a separate run, 7 lanes of 38-base paired-end sequencing.
Sequencing runs all used the Illumina Sequencing Kit v3-36
reagents. Sequencing data from this study are available on the
SRA through dbGaP.
Selection of Fusion Candidates from Paired End Reads
As seen in Figure S1, reads from two 76-base, paired-end lanes
and seven 38-base, paired-end lanes were passed through the
Illumina PF filter and aligned using Bowtie [40] to the hg19
RefSeq transcriptome as paired-end reads. Those paired ends that
successfully aligned were put aside as they do not represent novel
fusion events. The paired-end sequences that failed this alignment
were then subjected to alignments of each end separately with a
more stringent requirement for unique alignment within the
RefSeq transcriptome. Paired reads, of which side 1 mapped
uniquely to a RefSeq annotated gene (gene A) and side 2 mapped
uniquely to a different RefSeq annotated gene (gene B), were taken
as indirect evidence of a fusion between gene A and gene B. A
FASTA file of all exon-exon junctions between gene A and gene B
was generated; reads that failed to align to the reference
transcriptome were aligned to this FASTA file of exon-exon
junctions. 76-mer reads that aligned to a junction between genes A
and B, including at least 10 bp overlap on each side of the
junction, and whose mate mapped to either gene A or gene B,
were subjected to further analysis.
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cDNA was prepared with SuperScript III First-Strand Synthesis
kit, PCR amplifications were performed with Platinum Taq DNA
Polymerase, and products were cloned with TOPO TA Cloning
kits, all from Invitrogen (Carlsbad, CA, USA).
For initial RT-PCR validation in the RNA pool, we used primers
G1P1-FWD = 59-GGCATTGAGCCTCTCTACATCA-39(ESRRA
exon 2) and G2P1-REV = 59-TCGATGTATCGCTGCAGCT-
CCTTA-39 (C11orf20 exon 5). PCR was run for 40 cycles; each cycle
was 94uC1 5s ,5 5 uC3 0s ,7 0 uC6 0s .
For screening offusion transcript prevalence, we used a nested RT-
PCR for increased specificity. For each sample, we performed up to 6
technical replicates, and only considered positive if a majority of
replicates gave a fusion product. The outer primers were G1P1-
FWD = 59-GGCATTGAGCCTCTCTACATCA-39 (ESRRA)
and REV_pair3 = 59-GGGTCAGGCTTGGGTCTG-39 (C11orf-
20); the inner primers were G1P2-FWD = 59-AAAGGGTT-
CCTCGGAGACAGAGA-39 (ESRRA) and F1-REV = 59-
TAATTCACGTACAGCCTCTTGCTCCG-39 (C11orf20). The
outer PCR was run for 20 cycles, then diluted 1/200 into inner
PCRmix,andrunfor30cycles;eachcyclewas94uC1 5s ,5 5 uC3 0s ,
72uC6 0s .
Hybrid-Selection and UHTS of Genomic DNA:
Tissue samples were obtained from two FHCRC patients whose
tumor samples expressed the ESRRA-C11ORF20 fusion tran-
script (one tumor lacked a matched normal). The samples were
processed using TRIZOL (Invitrogen) to extract RNA and
genomic DNA.
The DNA samples were sheared to an intended size of 400 bp
in Covaris sample tubes (part # 500111; Covaris, Inc., Woburn,
MA, USA) in a Covaris S2 controlled by SonoLab software, using
settings of 10% duty cycle, intensity 4, 200 cycles per burst, for two
30-s periods.
We generally followed the Illumina protocol for hybridization
enrichment libraries, using Herculase II Fusion Enzyme (Agilent,
Santa Clara, CA, USA) for PCR amplification. Samples were
purified between steps using Agencourt AMPure SPRI XP beads
(Beckman Coulter, Brea, CA, USA).
Hybrid-selection of the Illumina genomic libraries was based on
[41–43]. A fully sequenced BAC, RP11-783K16 (GenBank #
AP001453) encompassing the C11orf20-ESRRA region, was
obtained from BACPAC Resource Center (Oakland, CA). BAC
DNA was biotinylated using a nick-translation kit (Roche Applied
Science, Indianapolis, IN). Illumina library (0.8 micrograms) was
hybridized at 65 uC for .24 h to biotinylated BAC DNA (0.2
micrograms) in a solution containing: Cot-1 DNA (4 micrograms),
sheared E. coli DNA (1 microgram), sheared vector DNA (0.5
micrograms), four adaptor-blocking oligos ([43]; 600 pmoles each),
in 56 SSPE, 5 mM EDTA, 56 Denhardt’s, 0.1% SDS (total
volume 24 microliters). The genomic library DNA that hybridized
to the BAC probe was captured on streptavidin-magnetic beads
(Dynal MyOne, Invitrogen), which were then washed and eluted
with 0.1 M NaOH. The eluate was precipitated and resuspended
in 60 microliters of water. 20 microliters of the resulting solution of
hybridization-selected genomic library DNA was amplified with
Illumina PCR primers for 18 cycles (within the exponential
amplification range), yielding ,1 microgram of product. Each
hybridization-selected genomic DNA library was sequenced on a
separate lane of an Illumina GAIIx flow cell.
Genomic Sequence Analysis
We identified read-pairs in the selected region where the
distance between the paired sequences in the reference genome
was greater than 1 kb—inconsistent with library insert sizes (which
were ,0.8 kb). The C11ORF20-ESRRA genomic region was
divided into bins. The counts of anomalous read-pairs were
compiled in a 2-dimensional histogram where each axis repre-
sented the genomic coordinate (bin) of one end of the read-pair,
with read 1 aligning in the (+) orientation and read2 aligning in the
(2) orientation. This was done for each sample, both tumors and
normals. Pile-ups were nominated for further consideration at a
given false discovery rate using a Poisson model for PE reads that
takes into account position-specific bias. This model and
subsequent analysis is detailed in Text S1.
The following computational approach was implemented to
discover highly represented sequences inconsistent with the
reference. A 20 kb radius around the transcriptional start of
ESRRA was discretized into 200 bp bins. For each bin, reads
where one read aligned to the plus strand and the other read failed
to align to the human genome hg19 build were flagged, and the
unaligned reads were consolidated and input to the de novo
assembler Velvet. The same procedure was followed for reads
where one read aligned to the minus strand. Velvet outputs
contigs: putative sequences assembled from input reads. These
contigs were subjected to further analysis by computationally
fragmenting each contig to tiling 80-mers and aligning these 80-
mers to the genome. In order to narrow our search to tumor-
specific rearrangements, only contigs with portions that failed to
align to the reference genome were scrutinized. Contigs which had
sample-specific representation in the sequencing data (i.e., present
in one tumor, and none of the remaining samples, or present in the
normal sample of one individual and none of the remaining
samples) were further scrutinized. The only such sequence with the
potential to directly explain a genomic configuration capable of
generating the fusion transcript was found in Tumor 1 and
confirmed by PCR (see Text S1). Sequencing data from this study
are available on the SRA through dbGaP.
Supporting Information
Figure S1 Detailed analysis pipeline for detection of fusion
transcripts in paired-end sequences from tumor RNA. The
pipeline for analysis of sequences from tumor RNA is schematized
with files in blue and Postgres tables in red. We start by aligning
paired-end reads to RefSeq using Bowtie, retaining reads which
failed to align (leftovers) in table read1 leftovers and read2
leftovers. The leftovers are re-aligned separately to RefSeq using
Bowtie with m = 1 (unique) and alignments retained as r1seq and
r2seq Postgres tables. We identify mate pairs in these alignments
where one gene (A) differs from the paired mate (B). We then
created a database of all A-B, B-A, A-A, and B-B junctions. We
created junctions using all the exons in each gene A and B from
the mate pair A-B as well as the exons within A and the exons
within B. All long (76 bp) purity filtered (PF) reads were then
aligned to the junction database, and successful alignments were
tracked by Postgres tables. We performed queries to select reads
with a transcriptome alignment as one half of a mate pair, and a
junction read-through on the other mate, resulting in a table of
fusion candidates.
(EPS)
Figure S2 Null hypothesis (fusions explained by homology)
versus alternative hypothesis (potentially real fusion). (A) Orienta-
tion of alignments of Paired End (PE) reads from potentially real
fusions at exon-exon boundaries. (B) Orientation of alignments of
PE reads from putative fusions arising from homology between
gene 1 and gene 2 at exon-exon boundaries. An intra-gene read
that matches to a fusion junction due to sequence homology (2nd
A Recurrent Gene Fusion in Ovarian Cancer
PLoS Biology | www.plosbiology.org 7 September 2011 | Volume 9 | Issue 9 | e1001156step) can be interpreted as evidence for a fusion, but has a polarity
inconsistent with the gene order in the fusion.
(EPS)
Figure S3 RT-PCR fusion products seen in the Ovarian Cancer
12 patient pool. Lanes 1 and 2 are beta-Actin controls, expected
353 bp product. Lane 3 is a negative beta-Actin control. Lanes 4
through 7 are fusion products. Lanes 4 and 6 RT used gene
specific primers G2P1-REV and G2P2-REV. Lanes 5 and 7 RT
used oligo(dT) primer. Lanes 4 and 5 PCR primers are G1P1-
FWD and G2P1-REV ‘‘pair-1.’’ Lanes 6 and 7 PCR primers are
G1P2-FWD and G2P2-REV ‘‘pair-2.’’ Lane 8 is a negative H2O
control. Lanes 9 and 10 are ladder: 100 bp, 250 bp, 400 bp,
800 bp, and 1,500 bp. Primer sequences and predicted product
sizes are given in Text S1.
(TIFF)
Table S1 Clinical samples. Clinical details (age, stage, grade,
histology, and chemotherapy) are shown for (1) the 42 patients
from FHCRC and (2) the 25 patients from BCCA. Fusion-positive
cases are indicated by shading and the isoforms identified are
given in the column ‘‘Observed Fusion Isoforms.’’
(XLS)
Table S2 Potential fusion candidates. The fusion candidates
derived from our RNA pipeline are listed, sorted by the first
column ‘‘Count,’’ which sums all the junctional reads involving a
given pair of genes. For each gene pair, the precise exons fused are
listed; when more than one distinct exon-exon junction was
identified, all are listed. In some cases of short exons, reads
matched to consecutive exons in a gene: for example ‘‘CO-
L1A1.exon10,11:COL1A2.exon1’’ indicates a match involving
both exon 10 and 11 of COL1A1 as the 59 side of the fusion. The
ESRRA-C11orf20 fusion studied in detail in this report has rank 2
in the list, with five junctional counts; four correspond to the E2-
C3 isoform and one to the E2-C4 isoform.
(XLS)
Text S1 Supporting text.
(DOC)
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